ACADIA Pharmaceuticals Files 8-K on Financials
Ticker: ACAD · Form: 8-K · Filed: 2024-08-06T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: ACAD
TL;DR
ACADIA dropped an 8-K on financials, check it for the latest numbers.
AI Summary
On August 6, 2024, ACADIA Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational details were provided in the excerpt.
Why It Matters
This filing indicates ACADIA Pharmaceuticals is providing updates on its financial performance and condition to the SEC, which is important for investors to assess the company's health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting routine financial and operational information, not indicating any immediate or unusual risks.
Key Players & Entities
- ACADIA Pharmaceuticals Inc. (company) — Registrant
- August 06, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The provided excerpt indicates the 8-K concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific figures within those sections.
When was this 8-K filing submitted to the SEC?
The filing was submitted on August 6, 2024.
What is ACADIA Pharmaceuticals Inc.'s principal executive office address?
The principal executive offices are located at 12830 El Camino Real, Suite 400, San Diego, California, 92130.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is ACADIA Pharmaceuticals Inc.'s IRS Employer Identification Number?
The IRS Employer Identification Number for ACADIA Pharmaceuticals Inc. is 06-1376651.
Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-08-06 16:13:44
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ACAD The Nasdaq Stock Mar
Filing Documents
- acad-20240806.htm (8-K) — 40KB
- acad-ex99_1.htm (EX-99.1) — 214KB
- 0000950170-24-091826.txt ( ) — 378KB
- acad-20240806.xsd (EX-101.SCH) — 24KB
- acad-20240806_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 6, 2024, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the second quarter and six months ended June 30, 2024. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated August 6, 2024. 104 Cover page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Acadia Pharmaceuticals Inc. Date: August 6, 2024 By: /s/ Jennifer J. Rhodes Jennifer J. Rhodes Executive Vice President, Chief Legal Officer & Secretary